Instem - Information Solutions For Life

Regions

• North America
• Europe
• China
• India
• Japan

United States

Although the number of new drug approvals are at an 8-year low, the United States market accounts for 43% of pharmaceutical sales worldwide with R&D investments reaching a record $58.8 billion in 2007. This represents an increase of nearly $3 billion from 2006 amidst a sluggish economy and growing cost pressures.

Despite such high levels of investment and increased demand, drug makers in fact are spending more on R&D but producing fewer drugs.

The US government continues to foster innovation which has resulted in the largest and most diverse pipeline in the world with US Pharmaceutical organizations consistently investing around 18% of sales on R&D activities.

Although the FDA’s Critical Path Initiative intended to speed the approval of new drugs, safety setbacks like those found with VIOXX , inter-agency politics and soaring costs have caused the drug development cycle to remain at approximately 14 years.

The Focus on Preclinical

There are great pressures for new discoveries and the preclinical phase has become the clear and consistent bottleneck. The US Pharmaceutical industry has turned to technology as one of their solutions, but is facing the reality that there are hundreds of isolated software applications across many of their locations. More than a desire, there is a confirmed need to consolidate vendor relationships while harmonizing software applications. This allows today’s Pharmaceutical organization to make informed decisions using consolidated knowledge while maximizing IT investments and resources.

Instem is the only vendor proactively responding to these industry needs and with its integrated solutions providing clients with a clear way forward amidst a fragmented technology market through traditional on-site or SaaS (Software-as-a-Service) solutions.

US Pharmaceutical firms also view their relationships with Contract Research Laboratories (CRO’s) as a critical link to increasing output and quality. As sponsors, they are placing heavy pressure on their CRO’s to automate using proven technologies while holding down costs. In response, contract laboratories continue to choose Instem solutions for their ease of use, proven investment returns and to help assure sponsors of their commitment.
By leveraging common Instem technology which commands more than 60% of the global preclinical IT market, CRO’s also attract and are able to serve a growing list of sponsors more efficiently and cost effectively.

Instem maintains the largest in-house sales, marketing, service & support teams in the US PreClinical IT market and invests more in product development annually than any other vendor in its market.